/
Other
Polymyalgia Rheumatica
5
Pipeline Programs↗
9
Active Trials↗
7
Companies Involved↗
Polymyalgia Rheumatica is an early-stage landscape with 5 programs across 7 companies. 3 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Programs by Phase
Phase 1
No programs
Phase 2
No programs
Approved
No programs
Analysis
Modality Breakdown
60%
Monoclonal antibody
3 of 5 classified programs — the dominant modality here.
Monoclonal antibody leads; the ring shows all 5 classified programs, each share of the total. Modality classified for 100% of 5 pipeline programs.
Analysis
Trial Status
33
clinical trials
Completed14 · 42%
Unknown status5 · 15%
Terminated4 · 12%
Recruiting3 · 9%
Not yet recruiting3 · 9%
Active, not recruiting3 · 9%
Other1 · 3%
Clinical Trials
Trial Activity
33 trials
Pilot Study to evaluateThrombomodulin to Rule Out Giant Cell Arteritis (GCA) in Polymyalgia Rheumatica (PMR) Patients. (THROPIQ)
Recruiting·—·N/A·NCT06609668·78 enrolled
Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR Relapse
Active, not recruiting·—·Phase 3·NCT05533164·174 enrolled
Efficacy and Safety of Ivarmacitinib in the Treatment of Patients With Polymyalgia Rheumatica
Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT07266168·80 enrolled
Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Recently Diagnosed
Completed·—·Phase 3·NCT05533125·114 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)